216 related articles for article (PubMed ID: 21385896)
1. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.
Akli S; Van Pelt CS; Bui T; Meijer L; Keyomarsi K
Cancer Res; 2011 May; 71(9):3377-86. PubMed ID: 21385896
[TBL] [Abstract][Full Text] [Related]
2. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Duong MT; Akli S; Wei C; Wingate HF; Liu W; Lu Y; Yi M; Mills GB; Hunt KK; Keyomarsi K
PLoS Genet; 2012; 8(3):e1002538. PubMed ID: 22479189
[TBL] [Abstract][Full Text] [Related]
3. Targeting low molecular weight cyclin E (LMW-E) in breast cancer.
Nanos-Webb A; Jabbour NA; Multani AS; Wingate H; Oumata N; Galons H; Joseph B; Meijer L; Hunt KK; Keyomarsi K
Breast Cancer Res Treat; 2012 Apr; 132(2):575-88. PubMed ID: 21695458
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
Akli S; Bui T; Wingate H; Biernacka A; Moulder S; Tucker SL; Hunt KK; Keyomarsi K
Clin Cancer Res; 2010 Feb; 16(4):1179-90. PubMed ID: 20145171
[TBL] [Abstract][Full Text] [Related]
6. Specific overexpression of cyclin E·CDK2 in early preinvasive and primary breast tumors in female ACI rats induced by estrogen.
Weroha SJ; Lingle WL; Hong Y; Li SA; Li JJ
Horm Cancer; 2010 Feb; 1(1):34-43. PubMed ID: 21761349
[TBL] [Abstract][Full Text] [Related]
7. Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.
Duong MT; Akli S; Macalou S; Biernacka A; Debeb BG; Yi M; Hunt KK; Keyomarsi K
Cancer Res; 2013 Sep; 73(17):5556-68. PubMed ID: 23955388
[TBL] [Abstract][Full Text] [Related]
8. Why are the truncated cyclin Es more effective CDK2 activators than the full-length isoforms?
Rath SL; Senapati S
Biochemistry; 2014 Jul; 53(28):4612-24. PubMed ID: 24947816
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
Doostan I; Karakas C; Kohansal M; Low KH; Ellis MJ; Olson JA; Suman VJ; Hunt KK; Moulder SL; Keyomarsi K
Clin Cancer Res; 2017 Dec; 23(23):7288-7300. PubMed ID: 28947566
[No Abstract] [Full Text] [Related]
10. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression.
Wingate H; Puskas A; Duong M; Bui T; Richardson D; Liu Y; Tucker SL; Van Pelt C; Meijer L; Hunt K; Keyomarsi K
Cell Cycle; 2009 Apr; 8(7):1062-8. PubMed ID: 19305161
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced cyclin E.
Cheng PH; Rao XM; McMasters KM; Zhou HS
PLoS One; 2013; 8(2):e57340. PubMed ID: 23437375
[TBL] [Abstract][Full Text] [Related]
12. Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo.
Hanse EA; Nelsen CJ; Goggin MM; Anttila CK; Mullany LK; Berthet C; Kaldis P; Crary GS; Kuriyama R; Albrecht JH
Cell Cycle; 2009 Sep; 8(17):2802-9. PubMed ID: 19652536
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.
Akli S; Zheng PJ; Multani AS; Wingate HF; Pathak S; Zhang N; Tucker SL; Chang S; Keyomarsi K
Cancer Res; 2004 May; 64(9):3198-208. PubMed ID: 15126360
[TBL] [Abstract][Full Text] [Related]
14. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation.
Delk NA; Hunt KK; Keyomarsi K
Cancer Res; 2009 Apr; 69(7):2817-25. PubMed ID: 19318554
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer.
Li M; Tsavachidis S; Wang F; Bui T; Nguyen TDT; Luo L; Multani AS; Bondy ML; Hunt KK; Keyomarsi K
Oncogene; 2022 Dec; 41(50):5331-5346. PubMed ID: 36344674
[TBL] [Abstract][Full Text] [Related]
16. Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis.
Ray D; Terao Y; Christov K; Kaldis P; Kiyokawa H
Neoplasia; 2011 May; 13(5):439-44. PubMed ID: 21532884
[TBL] [Abstract][Full Text] [Related]
17. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.
Bagheri-Yarmand R; Nanos-Webb A; Biernacka A; Bui T; Keyomarsi K
Cancer Res; 2010 Jun; 70(12):5085-95. PubMed ID: 20530684
[TBL] [Abstract][Full Text] [Related]
18. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.
Caruso JA; Duong MT; Carey JPW; Hunt KK; Keyomarsi K
Cancer Res; 2018 Oct; 78(19):5481-5491. PubMed ID: 30194068
[TBL] [Abstract][Full Text] [Related]
19. Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines.
Cooley A; Zelivianski S; Jeruss JS
Cell Cycle; 2010 Dec; 9(24):4900-7. PubMed ID: 21150326
[TBL] [Abstract][Full Text] [Related]
20. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.
Wingate H; Zhang N; McGarhen MJ; Bedrosian I; Harper JW; Keyomarsi K
J Biol Chem; 2005 Apr; 280(15):15148-57. PubMed ID: 15708847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
